EU Flu Day Launched Today by MEP Dolors Montserrat With Vaccines Europe’s Support
14.10.2020 13:38:00 EEST | Business Wire | Press release
The first annual EU Flu Day is being launched today, 14 October 2020. The campaign seeks to highlight the importance of seasonal flu vaccination, particularly during the ongoing COVID-19 pandemic, and to address challenges for sustainable increase of flu vaccine coverage rates in Europe as a critical public health measure for healthcare systems sustainability.
It is a call to action for European citizens – particularly healthcare workers and at-risk groups – to make them aware of the need to be vaccinated against flu, in order to protect themselves, those around them as well as alleviating the stress on national health care systems.
The campaign is being spearheaded by Dolors Montserrat, a leading Member of the European Parliament (EPP, Spain) and Co-Chair of the Health Working Group. Montserrat is also a former Minister of Health in Spain. The campaign is being organised with the support of Vaccines Europe.
There are several activities being planned for EU Flu Day, including:
- #EUFluDay online campaign: EU Flu Day is an opportunity for policymakers and citizens alike to set an example. Everyone is encouraged to share a message about the importance of getting the flu vaccine on social media, using the hashtag #EUFluDay. EU policy makers have already begun posting messages of support (e.g. here, here, here), and several more are expected over the course of the day.
- EU Flu Day launch webinar: MEP Montserrat is holding a webinar to mark the launch of EU Flu Day, bringing together participants from the European Commission, World Health Organisation, European Parliament, healthcare professionals and the vaccines industry. It is titled “Flu vaccination as a public health measure during COVID-19” and is taking place from 14:00-16:00 CET on 14 October 2020. Speakers will share their views on optimal approaches to increase flu vaccine uptake during COVID-19. This will include how to overcome barriers with the uptake of seasonal flu vaccines, and how to ensure early supply forecast planning, given the long lead times for vaccine production. One key proposal is to extended window for flu vaccination, in order to meet the increased demand caused by a pandemic.
“We are calling on Europeans citizens, particularly health workers and at-risk groups, to get their seasonal flu vaccination, in order to protect themselves and others, and to avoid overwhelming national healthcare systems” said MEP Montserrat. “We want to do all we can to drive action to safeguard public health from seasonal influenza, especially in a COVID-19 setting. That’s why I am calling on EU policymakers to lead by example on 14 October – and throughout the entire season. With an annual EU Flu Day, we have an opportunity to improve flu vaccine uptake rates across the EU for future seasons. Only by taking steps like this can we safeguard public health in the face of a truly unprecedented crisis.”
The importance of flu vaccination during COVID-19
Seasonal flu vaccines are an essential part of the annual public health toolkit. It is estimated that there are up to 50 million cases of seasonal flu in Europe each year, causing up to 70,000 deaths. Seasonal flu also puts a large strain on healthcare systems, for example through hospitalisations. With the dual threat of seasonal flu and COVID-19, uptake of flu vaccines will be even more vital for public health during the 2020/2021 season to prevent the overwhelming of healthcare systems.
The WHO recommends that countries should aim for 75% flu vaccine coverage rate among at-risk groups. Yet no EU country currently meets this target. In fact, the latest available data shows an average uptake level of only 41% of those aged 65 and over, with the lowest score being only 7.7%, while some Member States are above 60%.
The COVID-19 pandemic has increased public awareness of the need for each person to take steps that protect the wider community – particularly those in at-risk groups. Seasonal flu vaccines are one of the most effective ways people can protect themselves, others and healthcare systems, particularly in a COVID-19 pandemic setting. Depending on local recommendations, flu vaccination might be prioritised to at-risk groups at the start of vaccination season, however it is important to note that people - both in and outside scope of risk groups - should consider vaccination even until January and beyond as peak phase of flu can fall to February or March.
Magdalena R. De Azero, Executive Director of Vaccines Europe, said: “The vaccine industry is currently working around the clock to develop, manufacture and supply COVID-19 vaccines. While these efforts continue, manufacturers have also managed to marginally increase their flu vaccine production to cope with increased demand. These efforts should be supported with effective national flu vaccination campaigns to ensure optimal access and uptake.” She added that “flu is an annual public health threat with or without the concurrent pandemic. Therefore, EU Flu Day needs to be a springboard for action. We need to translate ideas into reality – like expanding access to flu vaccines in new healthcare settings like pharmacies, and implementing targeted vaccination campaigns to meet demands of seasonal flu vaccination administration in a COVID-19 setting. Policymakers at both EU and national level have an essential role to play in achieving this – both this year and beyond.”
Vaccines Europe is a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that represents major innovative research-based vaccine companies as well as small and medium-sized enterprises operating in Europe which account for a large share of human vaccines used worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005465/en/
Contact information
Media
Magdalena R. De Azero
Executive Director, Vaccines Europe
magdalena.deazero@vaccineseurope.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s.2 However, over 30% would have liked to learn about this in their 30s and over 50% are at best neutral or dissatisfied with their knowledge on the topic.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129610958/en/ To address this knowledge gap, Galderma will leverage its expertise in dermatology to advance awareness, understanding, education, and treatment approaches for menopause-related skin changes. With around 85% of aesthetic patients being female, it is important to
Convera Appoints Industry Leader Meaghan Riley as Chief Commercial Officer to Scale Commercial Growth and Expand Revenue Opportunities29.1.2026 18:14:00 EET | Press release
Convera, a global leader in commercial payments, today announces the appointment of Meaghan Riley to Chief Commercial Officer, as the company continues its growth trajectory, expands to new markets, and drives scalable revenue opportunities across geographies and sectors. Prior to Convera, Meaghan was Chief Operating Officer for Google Cloud North America, where she led a major go-to-market transformation and launched high-growth segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129799440/en/ Meaghan Riley, Chief Commercial Officer, Convera “Meaghan’s impressive career journey and proven track record brings exceptional experience and unique assets that will strengthen our leadership team at this pivotal moment in Convera’s journey,” said Patrick Gauthier, CEO, Convera. “Meaghan’s leadership will be instrumental in delivering on our commitment to make global business payments simpler and smarter—serving our customer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
